Overall survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival at 5‐year · women with early poor prognosis breast cancer
High‐dose chemotherapy showed no clear difference in overall survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
1 finding from 1 review
Overall survival (OS) · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (baseline risks for low‐ and high‐risk groups in the control arm were estimated at 1 year) · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in overall survival (baseline risks for low‐ and high‐risk groups in… compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
Overall survival: higher‐dose WBRT vs control (3000 cGy/10 daily fractions)No. of participants: 846(4 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules showed no clear difference in overall survival: higher‐dose WBRT vs control (3000 cGy/10 daily… compared with WBRT control (moderate certainty).
1 finding from 1 review
HR 0.97 [0.83, 1.12]
Studies not reported
Moderate
Intervention not reported
Mortality sensitivity analysis (calculated instead of overall survival) ‐ without UK NCRI Rapid trial and MSKCC trial #90‐44due to high risk of other bias
The intervention probably leads to lower mortality sensitivity analysis (calculated instead of overall… (moderate certainty).
1 finding from 1 review
Overall survival · high‐grade glioma
Daily conventionally fractionated radiotherapy probably leads to higher overall survival compared with no radiotherapy (supportive care alone) (moderate certainty).
1 finding from 1 review
Overall survival · high‐grade glioma
It is very uncertain whether hypofractionated radiotherapy changes overall survival compared with daily conventionally fractionated radiotherapy (very low certainty).
1 finding from 1 review
Overall survival · patients with high‐risk neuroblastoma
Rapid COJEC showed no clear difference in overall survival compared with standard induction therapies (low certainty).
1 finding from 1 review
Overall survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Overall survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Overall survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Overall survival (reported as mortality) · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower overall survival (reported as mortality) compared with standard therapy (moderate certainty).
1 finding from 1 review
Overall survival (reported as mortality) · high‐risk neuroblastoma patients treated with autologous HSCT
Retinoic acid postconsolidation therapy showed no clear difference in overall survival (reported as mortality) compared with no further treatment (low certainty).
1 finding from 1 review
Overall survival for subgroup age 60 years and older glioblastoma · high‐grade glioma
Hypofractionated radiotherapy showed no clear difference in overall survival for subgroup aged ≥ 60 years glioblastoma compared with daily conventionally fractionated radiotherapy (high certainty).
1 finding from 1 review
Overall survival ( · people with HGG
Anti‐angiogenic therapy showed no clear difference in overall survival ( compared with no anti‐angiogenic therapy (high certainty).
4 findings from 1 review
HR 0.95 [0.88, 1.02]
11 studies · 3743 participants
High
HR 0.93 [0.86, 1.02]
8 studies · 2833 participants
High
HR 0.99 [0.85, 1.16]
3 studies · 910 participants
Moderate
Show 1 more finding
Intervention not reported
Overall survival · people with non‐rhabdomyosarcoma soft tissue sarcoma
The intervention showed no clear difference in overall survival (high certainty).
1 finding from 1 review
Intervention not reported
Overall Survival · Adults with recurrent GBM
1 finding from 1 review
Intervention not reported
Overall survival · Adult patients with follicular lymphoma
The intervention showed no clear difference in overall survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall survival median · Adults with recurrent HGG
The intervention showed no clear difference in overall survival median (moderate certainty).
1 finding from 1 review